WALTHAM, MA / ACCESSWIRE / December 31, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, today announced that it has entered into a definitive agreement with certain institutional investors to purchase 500,000 shares of the Company's common stock at a purchase price of $10.00 per share, for aggregate gross proceeds of $5.0 million in a registered direct offering priced at-the-market under Nasdaq Rules.

The closing of the offering is expected to take place on or about January 3, 2020, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

EyeGate intends to use the net proceeds to obtain additional capital to support its operations, including for clinical trials, for working capital and for other general corporate purposes, which will include the pursuit of other research and development efforts and could also include the acquisition or in-license of other products, product candidates or technologies, though no such acquisition or in-license is current contemplated. EyeGate has not yet determined the amount of net proceeds to be used specifically for any of the foregoing purposes.

The shares of common stock described above will be offered and sold by EyeGate pursuant to an effective shelf registration statement on Form S-3 (file No. 333-231204), which was filed with the Securities and Exchange Commission (the "SEC") on May 3, 2019 and subsequently declared effective on May 13, 2019 (File No. 333-231204) (the "Registration Statement"), and the base prospectus dated as of May 13, 2019 contained therein. EyeGate will file a final prospectus supplement with the SEC in connection with the sale of the shares of its common stock and will be available on the SEC's website located at http://www.sec.gov. Electronic copies of the prospectus supplement and the accompanying base prospectus may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at 646-975-6996 or e-mail at placements@hcwco.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein. There shall not be any offer, solicitation of an offer to buy, or sale of securities in any state or jurisdiction in which such an offering, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About EyeGate

EyeGate is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products for treating diseases and disorders of the eye.

EyeGate's lead product, Ocular Bandage Gel ("OBG"), is based on a modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique properties providing hydration and healing when applied to the ocular surface. EyeGate is in the clinic for two different patient populations: photorefractive keratectomy ("PRK") surgery to demonstrate corneal wound repair and punctate epitheliopathies ("PE"), which includes the treatment of dry eye.

The objective of OBG is to re-epithelialize the cornea, reduce the risk of infection, improve symptoms, and improve ocular surface integrity. Often current treatments fall short as they are ineffective in protecting and enabling corneal re-epithelialization.

If EyeGate receives FDA approval following successful completion of the PRK pivotal study, EyeGate believes OBG will be the only prescription hyaluronic acid eye drop in the U.S. and the only eye drop in the U.S. approved for the healing of corneal epithelial defects. Additionally, if the clinical trials for patients with PE are successful, EyeGate believes OBG will be the only eye drop in the U.S. approved for the treatment of PE.

EGP-437, EyeGate's other product, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate, that is delivered into the ocular tissues through EyeGate's proprietary innovative drug delivery system, the EyeGate II Delivery System.

For more information, please visit www.EyeGatePharma.com.

EyeGate Social Media

EyeGate uses its website (www.EyeGatePharma.com), Facebook page (https://www.facebook.com/ EyeGatePharma/), corporate Twitter account (https://twitter.com/EyeGatePharma), and LinkedIn page (https://www.linkedin.com/company/135892/) as channels of distribution of information about EyeGate and its product candidates. Such information may be deemed material information, and EyeGate may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor EyeGate's website and its social media accounts in addition to following its press releases, SEC filings, public conference calls, and webcasts. The social media channels that EyeGate intends to use as a means of disclosing the information described above may be updated from time to time as listed on EyeGate's investor relations website.

Safe Harbor Statement

Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, EyeGate's expectations regarding the completion, timing, use of proceeds of the offering described in this press release, whether expressed or implied, the commercialization efforts and other regulatory or marketing approval efforts pertaining to EyeGate's products, including EyeGate's OBG product, as well as the success thereof, which approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, market conditions and certain risk factors described under the heading "Risk Factors" contained in EyeGate's Annual Report on Form 10-K filed with the SEC on March 1, 2019 or described in EyeGate's other public filings. EyeGate's results may also be affected by factors of which EyeGate is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. EyeGate expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based, except as required by law.

Contact
Joseph Green
Edison Advisors for EyeGate Pharmaceuticals
646-653-7030
jgreen@edisongroup.com
4833-6537-4128.4

SOURCE: Edison Group

ReleaseID: 571705

SAN FRANCISCO, CA / ACCESSWIRE / December 31, 2019 / The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in the class action litigation on behalf of investors who purchased or otherwise acquired the securities of Under Armour, Inc., ("Under Armour" or the "Company") (NYSE:UA; UAA) between September 16, 2015 and November 1, 2019, inclusive (the "Class Period").

If you purchased or otherwise acquired the securities of Under Armour during the Class Period, you may move the Court for appointment as lead plaintiff by no later than January 6, 2020. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the actions will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the actions.

Under Armour investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff should click here or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.

Background on the Under Armour Securities Class Litigation

Under Armour, based in Baltimore, Maryland, develops, markets, and distributes branded performance apparel, footwear, and accessories for men, women, and youth.

The actions allege that during the Class Period, Under Armour made false and/or misleading statements and/or failed to disclose that: (i) Under Armour improperly shifted sales from quarter to quarter to keep pace with their long-running year-over-year 20% net revenue growth; (ii) the Company had been subject to federal accounting probes since at least July 2017; and (iii) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On November 3, 2019, The Wall Street Journal reported that the U.S. Department of Justice ("DOJ") and the Securities Exchange Commission ("SEC") are investigating whether Under Armour shifted sales from quarter to quarter to appear healthier. On the following day, Under Armour confirmed that it was under DOJ and SEC investigations and has been responding to requests for documents and information regarding certain of its accounting practices and related disclosures, beginning with submissions to the SEC in July 2017. Following this news, the price of Under Armour Class A common stock fell $4.00 per share, or nearly 18.9%, to close at $17.14 per share, and its Class C common stock fell $3.47 per share, or 18.3%, to close at $15.44 per share.

About Lieff Cabraser

Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, and Nashville, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.

The National Law Journal has recognized Lieff Cabraser as one of the nation's top plaintiffs' law firms for fourteen years. In compiling the list, the National Law Journal examines recent verdicts and settlements and looked for firms "representing the best qualities of the plaintiffs' bar and that demonstrated unusual dedication and creativity." Law360 has selected Lieff Cabraser as one of the Top 50 law firms nationwide for litigation, highlighting our firm's "laser focus" and noting that our firm routinely finds itself "facing off against some of the largest and strongest defense law firms in the world." Benchmark Litigation has named Lieff Cabraser one of the "Top 10 Plaintiffs' Firms in America."

For more information about Lieff Cabraser and the firm's representation of investors, please visit https://www.lieffcabraser.com/.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Source/Contact for Media Inquiries Only

Sharon M. Lee
Lieff Cabraser Heimann & Bernstein, LLP
Telephone: 1-800-541-7358

SOURCE: Lieff Cabraser Heimann & Bernstein, LLP

ReleaseID: 571671

SAN FRANCISCO, CA / ACCESSWIRE / December 31, 2019 / The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in the class action that has been filed on behalf of investors who purchased or otherwise acquired the securities of Exelon Corporation ("Exelon" or the "Company") (Nasdaq:EXC) between February 9, 2019 and November 1, 2019, inclusive (the "Class Period").

If you purchased or otherwise acquired the securities of Exelon during the Class Period, you may move the Court for appointment as lead plaintiff by no later than February 14, 2020. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the actions will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.

Exelon investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff should click here or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.

Exelon, incorporated in Pennsylvania and headquartered in Chicago, Illinois, is a utility services holding company that serves as the parent company of the Commonwealth Edison Company ("ComEd"), the largest electric utility in Illinois, and the sole electric provider in Chicago.

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Exelon and/or its employees were engaged in unlawful lobbying activities; (2) this conduct increased the risk of a criminal investigation into Exelon; (3) ComEd's revenues were partly the product of unlawful conduct and therefore unsustainable; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.

On July 15, 2019, Exelon disclosed that it had received a grand jury document subpoena from the U.S. Attorney's Office for the Northern District of Illinois ("USAO") concerning Exelon's "lobbying activities in the State of Illinois." On this news, the price of Exelon stock price fell $0.18 per share, or 0.37% from a previous closing price of $49.06 on July 12, 2019, to close at $48.88 per share on July 15, 2019.

On October 9, 2019, Exelon disclosed that the USAO sought records of communications with Illinois State Senator Martin Sandoval, chairman of the Illinois Senate Transportation Committee. Exelon also revealed that it had formed a Special Overnight Committee in June 2019 to oversee compliance with the subpoenas.

On October 15, 2019, shortly before market close, Exelon announced the departure of Chief Executive Officer Anne Pramaggiore, "effective immediately." On this news, Exelon's stock price dropped $2.15 per share, or 4.57% from a closing price of $47.06 on October 15, 2019, to close at $44.91 per share on October 16, 2019, on elevated trading volume.

On October 31, 2019, Exelon revealed that on October 22, 2019, the Securities and Exchange Commission had notified the Company that it had opened an investigation into Exelon's lobbying activities. On this news, the price of Exelon dropped $1.17 per share, or 2.51% from a previous closing price of $46.66 on October 30, 2019, to close at $45.49 per share on October 31, 2019.

The next day, on November 1, 2019, the Chicago Tribune reported that "a source with knowledge of the case in Chicago" confirmed that "Pramaggiore is one focus of the ongoing federal investigation." According to the same article, "the ComEd lobbying investigation dates to at least mid-May, when the FBI executed search warrants at the homes of former lobbyist Mike McClain of Quincy, a longtime confidant of House Speaker Michael Madigan, and of former 23rd Ward Ald. Michael Zalewski." Additionally, "the information sought by the FBI included records of communications among Madigan, McClain and Zalewski about attempts to obtain ComEd lobbying work for Zalewski." On this news, the price of Exelon stock declined an additional $0.15, or 0.33% from the previous day's close, to close at $45.34 per share on November 1, 2019.

About Lieff Cabraser

Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, and Nashville, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.

The National Law Journal has recognized Lieff Cabraser as one of the nation's top plaintiffs' law firms for fourteen years. In compiling the list, the National Law Journal examines recent verdicts and settlements and looked for firms "representing the best qualities of the plaintiffs' bar and that demonstrated unusual dedication and creativity." Law360 has selected Lieff Cabraser as one of the Top 50 law firms nationwide for litigation, highlighting our firm's "laser focus" and noting that our firm routinely finds itself "facing off against some of the largest and strongest defense law firms in the world." Benchmark Litigation has named Lieff Cabraser one of the "Top 10 Plaintiffs' Firms in America."

For more information about Lieff Cabraser and the firm's representation of investors, please visit https://www.lieffcabraser.com/.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Source/Contact for Media Inquiries Only

Sharon M. Lee
Lieff Cabraser Heimann & Bernstein, LLP
Telephone: 1-800-541-7358

SOURCE: Lieff Cabraser Heimann & Bernstein, LLP

ReleaseID: 571667

NEW YORK, NY / ACCESSWIRE / December 31, 2019 / Thomas Despin is one of the few entrepreneurs who wasn't satisfied with what he did till he knew it was of real value, regardless of the revenue it generated. The 28 year old took several initiatives including freelance copywriting, event management, ecommerce drop shipping and more before embracing sustainability as the new direction. He founded Reconnect, a 100% sustainable island living experience that enables visitors to connect with themselves, nature, and one another.

Located on 2km wide Virgin Island in Central Sulawesi, Indonesia called Buka Buka, Reconnect uses sustainable technologies and high impact social programs to not just preserve its nature but also empower it. Thomas aims to install a solar powered desalination plant to ensure an abundant availability of water not just for the visitors of Reconnect but also for the rest of the island as it is a scarce resource. Currently, the locals have to climb for about an hour in search of water.

It also has environmental programs such as the Coconut Journey Workshops that are aimed to teach the locals and visitors how to creatively use coconut husks, thousands of which are otherwise wasted. Locals will get to learn how to set up small side businesses and visitors will learn how to craft their own products. Another social program that Thomas hopes to implement in Reconnect's initial years of launch involves coral transplantation. He acknowledges the fact that Indonesia is home to one of the largest coral reefs in the world that have been damaged now. For this reason, he aims to work with specialized organizations to improve the reef resulting in healthier ecosystem and more marine life. The program will also generate a lot of educational content for locals and visitors. He also came to realize the fact that there was some negative environmental impact that went in building the structures of the resort which is why Thomas intends to plant twice the number of trees cut to offset the impact and give back more than he took.

Reconnect offers an authentic and immersive island experience to its visitors. It has the adventurous facilities for its visitors including living in the luxury bungalows or glamping tents, observing the marine life through snorkeling, or paddling around the island in traditional kayaks. However, it also allows visitors to experience the day to day life of the locals on the island by joining them in climbing through the forest to get fresh water, learning from the locals how to make coconut oil, growing food in permaculture garden, planting trees, transplanting corals and much more. The eco resort is set to officially open in early 2020 but the team is accepting selected guests who would like to contribute to its completion.

Thomas is also the founder of Hustler's Villa, a coworking place in Ubud, Bali dedicated to a small scale community of entrepreneurs and freelancers who mostly work online. The place is tailored specifically to meet their needs. It also organizes free events where people can practice public speaking, network etc. Hustler's Villa has hosted more than 250 entrepreneurs and 60 events.

Before adopting sustainability as his new direction, Thomas made a mark in the ecommerce industry through his drop shipping business. Though it made $750,000 worth of sales in 11 months, he was highly dissatisfied and demotivated as he just wasn't up for pursuing something that wasn't of any real value. He felt like he didn't care about the product or the customer nor did he feel like he was learning something and felt he could use his skills for something more meaningful.

Thomas' latest venture speaks a lot about the extent to which he cares about creating something of value. Despite the cultural and financial hurdles, he was adamant on his quest to not only preserve nature but to contribute in strengthening it. His mindset has completely changed and he hopes to inspire change amongst the locals and visitors and lead by example.

Contact:

Thomas Despin
hi@reconnect.id

SOURCE: Mogul Press

ReleaseID: 571704

VANCOUVER, BC / ACCESSWIRE / December 31, 2019 / Red Lake Gold Inc. (CSE:RGLD)(FWB:P11) ("Red Lake Gold" or the "Corporation") is pleased to provide the results of its inaugural airborne survey at its Whirlwind Jack Gold Project situated near Red Lake, Ontario.

"We are pleased with the high-quality sub-surface imaging that resulted from our 2,045 line-km magnetic survey which was completed during the fourth quarter. The results provide demonstration of the continuity of the LP Fault structure extending on to Red Lake Gold's Whirlwind Jack Gold Project. The magnetic survey has also been successful in defining an exploration corridor within which Red Lake Gold can focus exploration efforts during the upcoming year. In addition, much of the project remains available for inaugural airborne surveys thereby providing us further exploration opportunities as we work to explore this district-scale project," stated Ryan Kalt, CEO of Red Lake Gold.

Fall 2019 Airborne Survey

The completed airborne survey was flown in a systematic low-level grid pattern and was focused on approximately one-third of the district-scale 211.8 km2 project commencing on an east to-west basis starting at the Corporation's contiguous claim boundary with Great Bear Resources Ltd.'s Dixie Gold Project. The survey covered 2,045 line-km on a 50m spacing basis (see news release, Red Lake Gold Inc. Commences 2,045 Line KM High-Resolution Aeromagnetic Survey at Whirlwind Jack Gold Project dated November 8, 2019).

The survey results from the airborne exploration conducted by Red Lake Gold have provided clarity and detail that supplements previously available but widely-spaced government data.

To assist with the development of the Whirlwind Jack Gold Project, the Company has internally segmented the project into three sub-components, covering approximately one-third of the project each, being Whirlwind Jack – West, Whirlwind Jack – Central and Whirlwind Jack – East. The 2,045 line-km data released today (which was the area flown in the aforementioned survey) covers only the portion underlying Whirlwind Jack – East. Both Whirlwind Jack – West and Whirlwind Jack – Central remain untapped as future opportunity sets for airborne-based exploration.

Survey Highlights

Highlights of the airborne survey completed by Red Lake Gold at Whirlwind Jack – East include:

• LP Fault Structure – The survey has provided data that allows for the interpretation of the LP Fault structure (as first defined by Great Bear Resources Ltd on the adjacent Dixie Gold Project) extending across the surveyed area into the Whirlwind Jack Gold Project. Results of the airborne have also led to the expansion of an area of interest by Red Lake Gold to a much broader, one km zone of prospective stratigraphy and structure within what is concluded to be a western extension of the LP Fault structure. This zone extends westward for a minimum of 12 km on the Whirlwind Jack Gold Project.

• Lithology – The LP Fault structure interpreted on the Whirlwind Jack Gold Project is situated within a deep magnetic low. The structure, a broad East-West trending deformation zone, is hosted by a repeated mafic-felsic volcanic sequence with intercalated sediments.

• Regional Splays/Offsets – The surveyed area has also revealed multiple splays and offsets from the interpreted LP Fault structure which could in turn provide for fluid flow environments that may lead to the future delineation of additional exploration targets. These various regional splays and offsets will require further follow-up by Red Lake Gold.

Figure 1: Fall 2019 Airborne Survey Coverage (TMI – Total magnetic intensity) (Whirlwind Jack – East)(URL link: https://bit.ly/2QChX84)

The magnetic low corridor adjacent to the interpreted LP Fault structure extending from the border of the contiguous Dixie Gold Project held by Great Bear Resources Ltd. will be an exploration focus for Red Lake Gold during the upcoming year.

At the contiguous Dixie Gold Project, the LP Fault structure defined by Great Bear Resources Ltd. represents a major break/deformation zone between felsic and mafic volcanic rocks and is associated with significant gold-bearing alteration (see news release issued by Great Bear Resources Ltd., Great Bear Completes 14 Drill Fences Along 3.2 Kilometres of the LP Fault dated September 30, 2019).

Observations made during the fall ground truthing program (see news release, Red Lake Gold Inc. Commences Field Exploration at Whirlwind Jack Gold Project dated September 18, 2019) confirmed a low-topographical profile at Whirlwind Jack – East suggestive of a soil setting that may be amenable to a soil sampling program, including the potential for Spatiotemporal Geochemical Hydrocarbons ("SGH") soil sampling which has been deployed at adjacent and regionally proximate projects.

For more information on the Whirlwind Jack Gold Project, please visit www.RedLakeGold.ca.

The Corporation cautions that results or discoveries on adjacent properties (i.e. Dixie) may not necessarily be indicative as to the presence of mineralization on the Corporation's property (i.e. Whirlwind Jack).

Qualified Person

Toby Hughes, P.Geo., P.Geol., is the Qualified Person as defined in Canadian National Instrument- 43-101, who has reviewed and is responsible for the technical information presented in this news release.

On Behalf of the Board of Directors

Ryan Kalt
Chairman & Chief Executive Officer
Email: info@redlakegold.ca

Forward-Looking Statements

This news release contains forward-looking statements. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently expected or forecast in such statements.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Red Lake Gold Inc.

ReleaseID: 571690

VANCOUVER, BC / ACCESSWIRE / December 31, 2019 /  Black Tusk Resources Inc. (the "Company") (CSE:TUSK)(Frankfurt:0NB)(OTC PINK:BTKRF) is pleased to announce that it has closed its second and final tranche of its flow-through private placement issuing an additional 845,000 Units (as defined below) at a price of $0.055 per Unit for total proceeds of $46,475. Including the previous tranche (see press release dated December 20, 2019), the total number of Units sold under this offering was 4,145,000 for total proceeds of $227,975.

Each Unit consists of one flow-through common share (a "Share") and one half of one share purchase warrant (each whole warrant a "Warrant"). Each Warrant will entitle the holder to purchase an additional share at a price of $0.10 per share for a two-year term (the "Warrant Term").

The Company paid finders fees to EMD Financial Inc. consisting of $2,997.50 cash, 32,700 common shares and 10,900 Warrants.

On behalf of the Board of Directors

Richard Penn,
CEO

CONTACT:

Roman Rubin
(CSE:TUSK)
Chief Financial Officer
500-666 Burrard st.
Vancouver, BC, V6C 3P6
Office: 604-373-TUSK (8875)
Toll free: 1-833-273-TUSK (8875)

SOURCE: Black Tusk Resources Inc.

ReleaseID: 571675

Company is Reclaiming Irrational Thermal Coal Mines While Continuing Its Growth of Metallurgical Carbon for Steelmaking

FISHERS, INDIANA / ACCESSWIRE / December 31, 2019 / American Resources Corporation (NASDAQ:AREC) ("American Resources" or the "Company"), a supplier of raw materials to the rapidly growing global infrastructure marketplace with a primary focus on the extraction, processing and distribution of metallurgical carbon to the steel and specialty alloy metals industries, is pleased to provide an update on its environmental reclamation of non-core mining properties. The Company's environmental focus is to continuously evaluate its mining permits and identify those properties that are at or below their proprietary (economic and environmental) margin and slate them for reclamation. Throughout the company's strategic acquisition plan, when an acquired mining complex involves both thermal and metallurgical properties, it immediately identifies such thermal coal permits, used for utility power generation, as below the margin.

American Resources, since inception, has strategically acquired and restructured mining complexes to set itself up for being one of the fastest growing, lowest cost metallurgical carbon platforms in the Central Appalachian basin over the next few years through cost cutting and right-sizing operations to fit the current and future market conditions. To date, American Resources has acquired over 75 mining permits with an associated reclamation bonding amount in excess of $36 million. To date, the Company has reclaimed, or is currently working to complete reclamation, on 25 thermal mining sites with an associated environmental reclamation liability of over $16.7 million.

Historically, the coal mining industry has deferred many environmental reclamation liabilities out for decades, instead of deeming such permits as "reclamation only" permits, in the hope that certain permits will rise above the margin and become active mines again in the future and/or to avoid permanent reclamation of such properties. American Resources, instead, has chosen not to defer that liability and deems such sites as "reclamation only" with a goal of remediating, and in certain cases, repurposing irrational mining sites that fall below the margin. Reclamation only permits are those that a company has decided to completely reclaim and not attempt to defer the reclamation work for a later time. This approach has resulted, at times, in the Company setting very aggressive reclamation deadlines for it to achieve. Consequently, as with many mining companies, this has caused American Resources to, at times, be named on the Office of Surface Mining Reclamation and Enforcement's (OSMRE) Applicant Violators System (AVS) list for trying to adhere to such aggressive final reclamation deadlines. As the Company expeditiously completes and progresses on this reclamation, it will naturally be removed from the AVS list, as the case with all other mining companies. Regardless, the Company and its team are proud of its desire to reduce the environmental footprint of its below-the-margin and thermal mines and remains focused exclusively on its specially metals and metallurgical carbon operations.

"Because our acquisition plan included complexes that often consisted of permits tied to both metallurgical carbon (used for steel making) and thermal coal (used for electricity generation), our strategic restructuring and environmental focus has been to separate the two assets by quality types.", stated Mark Jensen, Chief Executive Officer of American Resources Corporation. "Immediately post-acquisition, we then look to reclaim thermal coal mining sites that do not fit within our business model, while tying the metallurgical carbon assets into our existing operating growth platform. Our focus is to grow and expand our metallurgical carbon platform, but at the same time find efficient and viable solutions to either reclaim or repurpose the land associated with the thermal coal assets we acquire. Our goal here is to work with our partners to find the right solutions to benefit the environment and local communities, and in some cases create viable commercial uses for the land, while also reducing our overall environmental liability costs."

American Resources Corporation will continue to identify operational efficiencies and ways to reduce future liabilities in its continuing goal to be one of the lowest cost operators and responsible stewards of the environment in Central Appalachia and throughout all its coal mining, processing, and transportation operations.

About American Resources Corporation

American Resources Corporation is a supplier of raw materials to the rapidly growing global infrastructure marketplace. The company's primary focus is on the extraction, processing, transportation and selling of metallurgical carbon and pulverized coal injection (PCI) to the steel industry. The company operations are based in the Central Appalachian basin of eastern Kentucky and southern West Virginia where premium quality metallurgical products are located.

The company's business model is based on running a streamlined and efficient operation to economically extract and deliver resources to meet its customers' demands. By running operations with low or no legacy costs, American Resources Corporation works to maximize margins for its investors while being able to scale its operations to meet the growth of the global infrastructure market.

Website:
http://www.americanresourcescorp.com

Special Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that could cause the Company's actual results, performance, or achievements or industry results to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. These statements are subject to a number of risks and uncertainties, many of which are beyond American Resources Corporation's control. The words "believes", "may", "will", "should", "would", "could", "continue", "seeks", "anticipates", "plans", "expects", "intends", "estimates", or similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Any forward-looking statements included in this press release are made only as of the date of this release. The Company does not undertake any obligation to update or supplement any forward-looking statements to reflect subsequent events or circumstances. The Company cannot assure you that the projected results or events will be achieved.

Institutional/Retail/Individual Contact:

PCG Advisory
Adam Holdsworth
646-862-4607
adamh@pcgadvisory.com
www.pcgadvisory.com

Company Contact:
Mark LaVerghetta
317-855-9926 ext. 0
Vice President of Corporate Finance and Communications
investor@americanresourcescorp.com

SOURCE: American Resources Corporation

ReleaseID: 571691

ENGLEWOOD, CO / ACCESSWIRE / December 31, 2019 /  Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, announced today that it has been notified by Nasdaq that Viveve has regained compliance with the Nasdaq Capital Market continued listing requirements, the scheduled hearing before the Nasdaq Hearings Panel has been cancelled, and Viveve will continue to trade on the Nasdaq Capital Market.

About Viveve

Viveve Medical, Inc. is a medical technology company focused on women's intimate health. Viveve is committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System incorporates CMRF technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate neocollagenesis in a single in-office session.

In the United States, the Viveve System is cleared by the U.S. Food and Drug Administration (FDA) for use in general surgical procedures for electrocoagulation and hemostasis. International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications in more than 50 countries. Viveve is conducting VIVEVE II, a multicenter, randomized, double-blind, sham-controlled clinical trial to assess improvement of sexual function in women following vaginal childbirth. Completion of full 250 subject enrollment was announced in early March 2019. The top-line 12-month data readout of the VIVEVE II trial is expected in April 2020. If successful, VIVEVE II results could support a marketing application for a new U.S. commercial indication.

Viveve continues to advance its clinical development program in stress urinary incontinence (SUI) and plans to initiate a short-term feasibility study in the first quarter 2020 following the recently announced approval of the submitted Investigational Testing Application by the Canadian Ministry of Health. Following the positive yet inconclusive results of the LIBERATE-International trial, the planned feasibility study will be a single-blind, three-arm, three-month study to compare Viveve's CMRF treatment to cryogen-only treatment and to inert sham treatment in order to capture short-term safety and effectiveness data on use of the Viveve System for the improvement of SUI in women. Results of the planned three-month feasibility study are targeted for read-out in April 2020. If positive, the results could be used to support Viveve's re-submission of its Investigational Device Exemption to the FDA for approval to conduct the LIBERATE-U.S. trial designed to evaluate the safety and effectiveness of the Viveve System for improvement of SUI in women. The results of these trials, if successful, could support marketing applications in the U.S. and over 30 countries around the world for this new commercial indication.

For more information visit Viveve's website at www.viveve.com.

Safe Harbor Statement

All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing or pursue strategic alternatives, our ability to obtain approval or clearance for sale of our medical device for all indications sought, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware, unless required by law.

Investor Relations contacts:

Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com

Media contact:

Jenna Urban
Berry & Company Public Relations
(212) 253-8881
jurban@berrypr.com

SOURCE: Viveve Medical, Inc.

ReleaseID: 571689